Oppenheimer Maintains Outperform on Passage Bio, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 90.7%

Neg 90.7% Neu 0% Pos 0%

Oppenheimer analyst Jay Olson maintains Passage Bio (NASDAQ:PASG) with a Outperform and lowers the price target from $30 to $15.